Showing results (151-160 of 162) with videos related to
Sort By:
Pageof 17
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1993
Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120H Ehrenreich, P Rieckmann, F Sinowatz, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2000
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survivalA Mocroft, S Madge, A M Johnson, et al.AIDS (London, England)|March 15, 1997
Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS. AIDS in Europe Study GroupP Hermans, J Lundgren, B Sommereijns, et al.Research in Experimental Medicine. Zeitschrift Fur Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie|January 1, 1992
Long term monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhageH Ehrenreich, M Lange, K A Near, et al.Journal of Neurology|July 1, 1989
Myelin basic protein in the cerebrospinal fluid of patients infected with HIVH W Pfister, K M Einhäupl, M Wick, et al.Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|February 24, 1998
Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virusK Hartmann, M Kuffer, J Balzarini, et al.The New England Journal of Medicine|July 29, 1993
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative GroupD A Cooper, J M Gatell, S Kroon, et al.Infection|November 1, 1995
Pharmacokinetics of orally administered zidovudine in HIV-infected children and adultsU Wintergerst, B Rolinski, M Vocks-Hauck, et al.AIDS (London, England)|February 24, 2001
Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapyF D Goebel, R Hemmer, J C Schmit, et al.AIDS (London, England)|August 28, 1999
Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study GroupF D Goebel, J W Mannhalter, R B Belshe, et al.Pageof 17